This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Bas Groenendaal, Ph.D.
Director CMC at Vico Therapeutics B.V.


Bas obtained his PhD in organic chemistry in the group of Prof. Romano Orru at the Vrije Universiteit Amsterdam, followed by a post-doc in the group of Prof. Nicholas Turner at the Manchester Institute of Biotechnology. He joined Prosensa (later BioMarin Nederland) as a scientist in the CMC department in 2013; first working in the lab on the in-house manufacturing of oligonucleotide batches, and later on becoming responsible of the supply of both internally and externally produced batches. He is currently Director CMC at Vico Therapeutics where he manages the complete CMC trajectory for VICO’s assets.

Agenda Sessions

  • Structural Characterization of Oligonucleotides – Lessons Learned